PHARMDBIOLOGICSTRAININGPROGRAMAT REGENERON,EVERYTHINGSTARTS WITH SCIENCE

At Regeneron we make it our business every day to bring innovative thinking to the challenge of discovering and developing new medicines. Our pursuit has one singular intent – to improve therapeutic outcomes for patients.

ABOUT THE COMPANY

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

1.

2.

3.

4.

5.

SCIENCE drives our business and PASSION drives our science.

We are a select TEAM.

You will be CHALLENGED every day.

“That’s the way we’ve ALWAYS DONE IT,” is the WRONG ANSWER.

We won’t let BUREAUCRACY block good IDEAS.

THEREGENERONFIVE

THEENGINETO MAKE IT AREALITY

7 FDA-approved products~20 antibodies in the clinic

The Regeneron Genetics Center has sequenced the DNA of 400,000+ people to date.

8 investigational medicines in late-stage studies

8.5M doses of EYLEA® (aflibercept) injection delivered since launching in 2011.

Regeneron has been ranked the #1 employer by Science magazine for 6 of the past 8 years.

More than 7,000 employees

MARKETED PRODUCTS

TECHNOLOGY PLATFORMS

FULLY HUMAN MONOCLONAL ANTIBODIES

Regeneron has developed a suite of patented technologies (VelociSuite®), includingVelociGene®, VelocImmune® and VelociMab®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

FUSION PROTEINSOur novel and patented “Trap” fusion protein technology creates high-affinity product candidates for manydifferent types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.

CEMIPLIMAB* PD-1 Antibody | CancerREGN1979 CD20 X CD3 Antibody | CancerREGN3767* LAG-3 Antibody | CancerCEMIPLIMAB + REGN1979 PD-1 Antibody + CD20 X CD3 Antibody CancerCEMIPLIMAB + REGN3767* PD-1 Antibody + LAG3 Antibody | CancerREGN4659* CTLA4 antibody | CancerREGN4018* MUC16 X CD3 Antibody | CancerREGN-EB3 (REGN3470-3471-3479) Antibody to Ebola virus | Ebola virus infectionREGN3048-3051 Antibody to Middle Eastern Respiratory Coronavirus | MERS-CoV infectionGARETOSMAB + TREVOGRUMAB Activin A Antibody + GDF8 Antibody Muscle-wasting diseasesREGN1908-1909 Fel d 1 Antibody | Allergic diseasesPOZELIMAB C5 Antibody | Paroxysmal nocturnal hemoglobinuriaREGN4461 LEPR Antibody | Lipodystrophy and obesity

EVINACUMAB ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH)DUPILUMAB* IL-4R Antibody Eosinophilic esophagitisSARILUMAB* IL-6R Antibody Polyarticular-course juvenile idiopathic arthritisCEMIPLIMAB* PD-1 Antibody Cutaneous squamous cell carcinoma, basal cell carcinomaGARETOSMAB Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)REGN3500* IL-33 Antibody Asthma

ALIROCUMAB* PCSK9 Antibody Hypercholesterolemia, LDL cholesterol reduction and prevention of cardiovascular eventsDUPILUMAB* IL-4R Antibody Atopic dermatitis in pediatrics and adolescents, asthma in adults and adolescents, pediatric asthma, nasal polypsEVINACUMAB ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)AFLIBERCEPT VEGF-Trap Non-proliferative diabetic retinopathy (NPDR) without DMEFASINUMAB† NGF Antibody Osteoarthritis pain, chronic lower back painCEMIPLIMAB* PD-1 Antibody Non-small cell lung cancer, cervical cancer

PHASE1

PHASE2

PHASE3

*in collaboration with Sanofi† in collaboration with Teva and Mitsubishi Tanabe

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

OUR

PIPE

LINE

: A P

OWER

FUL R

ESEA

RCH

AND

DEVE

LOPM

ENT

ENGI

NE

PharmD Associates will:n Gain knowledge of biopharmaceutical development in a variety

of clinical development related rolesn Develop a balanced foundation of skills through hands-on

experience in industry areas such as clinical development and regulatory affairs

n Cultivate technical and non-technical skills through diverse cross functional experiences, ongoing mentorship, and targeted training

n Engage in interdisciplinary professional development sessions to maximize the learning and overall experience at Regeneron

The PharmD Biologics Training Program (BTP) is an intensive, interdisciplinary program for graduating PharmD candidates. The objective for the BTP is to provide training by Regeneron subject matter experts and hands-on experience in a variety of global development roles. The BTP is for highly motivated individuals seeking to build a career in the bio-pharmaceutical industry with a foundation in Clinical Sciences, Clinical Operations and Regulatory Affairs outside of a traditional academic environment.

OBJECTIVES

PHARMD BIOLOGICSTRAININGPROGRAM

This unique program is the foundation for potential roles within Global Development. The program cultivates technical and non-technical skills through diverse cross functional experiences, ongoing mentorship, and targeted training. Each assignment in this two-year development program will expose candidates to critical issues and decision-making processes to gain broad experience across several clinical/scientific research areas. The selected program participants will acquire high level knowledge of the business and department operations, as well as gain hands-on work experience in a variety of areas.

PHARMD BIOLOGICSTRAININGPROGRAM

n Clinical Project Management n Data Management n Regulatory Affairs

● Labeling ● Chemistry, Manufacturing

and Controls ● Advertising and Promotion ● Submission Project Management

PROGRAM STRUCTUREThe two-year program consists of core and elective rotations in the following areas:

CORE ROTATIONSn Clinical Development (Clinical Sciences and Operations)n Regulatory Affairs (Regulatory Affairs Clinical and Regulatory

Affairs Labeling)

ELECTIVE ROTATIONSn Medical Affairs

● Headquarters and field-based activities

● Medical Information● Health Economics and

Outcomes Research● Medical Education

n Pharmacovigilance and Risk Management

n Clinical Pharmacology ● Pharmacokinetics ● Pharmacodynamics ● Modeling

WHO IS THE PERFECT BTP CANDIDATE?The ideal applicant is flexible, intellectually curious, hard-working and passionate about science and continuous learning.

The candidate graduated from an accredited pharmacy program. These individuals have a high academic standing with preferably some research experience. They have strong analytical, communication and organization skills, and are adept at leadership and team roles.

“The Biologics Training Program at Regeneron offers a hands-on experiential approach within different functional areas in the biopharmaceutical industry. The environment at Regeneron reflects the company culture: it encourages personal development, growth, and intellectual learning.”

Andrew is in his first year of the PharmD Biologics Training Program, currently completing a rotation in early clinical development and clinical operations. He is focused in the inflammation and immunology therapeutic areas during this rotation, and will enter his next rotation in regulatory affairs.

“This training program allows you to gain expe-rience in core functional areas under the men-torship of experienced leaders. Everybody at Regeneron is passionate about science and using science to improve the lives of patients. It’s an inspiring place to work and grow.”

Sarah is completing a clinical development rotation with a focus on the immuno-oncology programs. She will transition to her regulatory affairs rotation in the coming months.

Andrew Kordahi, University of Cincinnati

Sarah-Ann Willette, University of Connecticut

CURRENT FIRST YEAR PHARMD ASSOCIATES

CURRENT SECOND YEAR PHARMD ASSOCIATES

“The flexibility of the program and openness of the culture at Regeneron allows you to shape your learning experience and professional growth. I’ve enjoyed working across different therapeutic areas and gaining a robust understanding

of clinical development from multiple perspectives.”

Jennifer currently supports Medical Affairs activities in immuno-oncology, including medical education, publications, and health economics and outcomes.

“The program allows you to gain exposure to multiple functional areas and understand drug development. I was fully integrated into my teams and able to contribute.”

Aakansha is finishing up her elective rotation in Program Management, supporting multiple projects within the immuno-oncology portfolio.

Aakansha Bhalla, Northeastern University

Jennifer Liang, University of Michigan

Elizabeth Bradley,Associate ManagerRegulatory Affairs

Joseph Gervasio,ManagerMedical Affairs

CURRENT ALUMNI

Krystal Sing, Associate ManagerMedical Information

TO BE ELIGIBLE FOR AN INTERVIEW AT ASHP MIDYEAR, YOU MUST COMPLETE THE FOLLOWING:n Apply through PPS

n Apply through Regeneron’s career website: https://careers.regeneron.com/

n Answer questions sent to you by Regeneron*

VIEW AND APPLY TO THE POSITION ON ASHP’S PERSONNEL PLACEMENT SERVICE (PPS) PORTAL:n Applications should include the following materials:

Resume/CV and Cover Lettern Interviews will be schedule through PPS and conducted on-site at the ASHP

Midyear Clinical Meeting

IF YOU HAVE QUESTIONS, PLEASE CONTACT:n Natalie Griffith (natalie.griffith@regeneron.com

n Sarah-Ann Willette (sarahann.willette@regeneron.com)

WANT TOBE PARTOF THE BTP?

* A link with questions and instruction on how to answer the questions will be emailed to you within 3 business of completing your application

ABOUT OUR LOCATIONThe PharmD Biologics Training Program is located in Tarrytown, NY. Tarrytown is located along the eastern bank of the Hudson River, about 25 miles north of midtown Manhattan.

In 2012, Forbes named Tarrytown as one of the prettiest towns in America and was ranked second in the top 10 places to live in New York State for 2014 according to the national online real estate brokerage, Movoto.

GEORGE D. YANCOPOULOS, M.D., PH.D.,PRESIDENT AND CHIEF SCIENTIFIC OFFICER, REGENERON“Regeneron has become one of the great science-driven companies of our generation, with six approved treatments, an entirely homegrown pipeline and the best technologies in the business. We got here by following the science and trusting our people. But at Regeneron, we’re never done. Our goal is to continue pushing the boundaries of science, to the extent that we aren’t even able to image the breakthroughs and cures we will be known for in ten or twenty years. It’s an incredible time to be at Regeneron, as we stand on the edge of an unprecedented future.”

CREATE THE FUTURE YOU BELIEVE IN

AWARDS

REGENERON PHARMACEUTICALS INC. IS AN EQUAL OPPORTUNITY EMPLOYER

Science: #1 Top Employer, 2017

Fortune: Best Companies to Work for, 2017

MIT Technology Review: Top 10 Smartest Companies, 2017

Barron’s: World’s Best CEOs, 2016

Crain’s New York Business: Fast 50, 2015

Scrip Award: Clinical Advance of the Year, 2013

Civic 50: Most Community-Minded Companies in the Nation, 2017

Fortune: Future 50, 2017

Forbes: Top 10 Most Innovative Companies, 2017

Scrip Award: R&D Team of the Year, 2016

Shingo Prize: Operational Excellence, 2013

Scrip Award: Management Team of the Year, 2013